The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase
暂无分享,去创建一个
K. Gajiwala | N. Grodsky | Sergei L Timofeevski | A. Stewart | R. Ferre | Ben Bolanos | Junli Feng | Meirong Xu | T. Johnson | B. Murray | Sergei L. Timofeevski
[1] M. Prados,et al. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas , 2016, Oncotarget.
[2] Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase , 2016, Cell Communication and Signaling.
[3] Zheng-chao Tu,et al. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors. , 2016, Journal of medicinal chemistry.
[4] G. Getz,et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.
[5] Valentina Abet,et al. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. , 2015, European journal of medicinal chemistry.
[6] K. Davies,et al. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.
[7] B. Halmos,et al. AXL kinase as a novel target for cancer therapy , 2014, Oncotarget.
[8] I. Lax,et al. Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities , 2014, eLife.
[9] G. Chevé,et al. Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors , 2014, Molecular Cancer Therapeutics.
[10] Wei Liu,et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.
[11] Jae Cheol Lee,et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.
[12] G. Lemke. Biology of the TAM receptors. , 2013, Cold Spring Harbor perspectives in biology.
[13] C. Sheridan. First Axl inhibitor enters clinical trials , 2013, Nature Biotechnology.
[14] D. Cyranoski. iPS cells in humans , 2013, Nature Biotechnology.
[15] Wei Lu,et al. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. , 2013, Journal of medicinal chemistry.
[16] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[17] S. Frye,et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2012, ACS medicinal chemistry letters.
[18] N. Powell,et al. Novel and selective spiroindoline-based inhibitors of Sky kinase. , 2012, Bioorganic & medicinal chemistry letters.
[19] Anupam Verma,et al. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. , 2011, ACS medicinal chemistry letters.
[20] D. Bearss,et al. Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.
[21] T. Rosenberg,et al. A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases , 2011, Molecular vision.
[22] P. Darke,et al. Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met , 2011, The Journal of Biological Chemistry.
[23] S. Steinbacher,et al. The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. , 2010, Biochemistry.
[24] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[25] Bjørn Tore Gjertsen,et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.
[26] Pao-Chun Lin,et al. Cytoplasmic ACK1 Interaction with Multiple Receptor Tyrosine Kinases Is Mediated by Grb2 , 2009, The Journal of Biological Chemistry.
[27] Joel Greshock,et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.
[28] A. Pozzi,et al. The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.
[29] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[30] J. Christensen,et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.
[31] G. Feldmann,et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.
[32] Xudong Huang,et al. Structural insights into the inhibited states of the Mer receptor tyrosine kinase , 2009, Journal of structural biology.
[33] Ming-Tseh Lin,et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.
[34] G. Lemke,et al. Immunobiology of the TAM receptors , 2008, Nature Reviews Immunology.
[35] A. Ullrich,et al. Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.
[36] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[37] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[38] H. Garewal,et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors , 2007, Oncogene.
[39] T. Pawson,et al. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases , 2006, The EMBO journal.
[40] Qingxian Lu,et al. TAM receptor function in the retinal pigment epithelium , 2006, Molecular and Cellular Neuroscience.
[41] R. Birge,et al. Phosphatidylserine recognition by phagocytes: a view to a kill. , 2006, Trends in cell biology.
[42] R. Timpl,et al. Structural basis for Gas6–Axl signalling , 2006, The EMBO journal.
[43] Susan S. Taylor,et al. Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.
[44] Stevan R. Hubbard,et al. Juxtamembrane autoinhibition in receptor tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.
[45] D. Murphy. Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. , 2004, Analytical biochemistry.
[46] B. Dahlbäck,et al. Ligand Recognition and Homophilic Interactions in Tyro3 , 2004, Journal of Biological Chemistry.
[47] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[48] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[49] Qingxian Lu,et al. Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family , 2001, Science.
[50] R. Scott,et al. Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.
[51] S. Jacobson,et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa , 2000, Nature Genetics.
[52] S. Goff,et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis , 1999, Nature.
[53] A. Ullrich,et al. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site , 1997, Oncogene.
[54] H. Hanafusa,et al. Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases* , 1996, The Journal of Biological Chemistry.
[55] H. Kung,et al. Identification of the Major Autophosphorylation Sites of Nyk/Mer, an NCAM-related Receptor Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.
[56] Pamela F. Jones,et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases , 1995, Cell.
[57] H. Yamane,et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 , 1995, Nature.
[58] J F Morrison,et al. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.